MENLO PARK, Calif. — February 9, 2026 — Leads & Copy — Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biotechnology company focused on developing novel biologics for chronic skin diseases, including plaque psoriasis, announced its participation and presentation at several upcoming conferences.
Oruka’s presentations will be available via webcast and replay on the company’s investor relations website.
The conferences include:
Guggenheim Emerging Outlook: Biotech Summit 2026, February 12th, 2026, at 10:30 AM ET.
TD Cowen 46th Annual Health Care Conference, March 3rd, 2026, at 1:10 PM ET.
UBS Biotech Summit Miami, March 9th, 2026.
Jefferies Biotech on the Beach Summit, March 10th, 2026.
Leerink Global Healthcare Conference, March 11th, 2026, at 1:00 PM ET.
Barclays 28th Annual Global Healthcare Conference, March 12th, 2026, at 10:30 AM ET.
Oruka Therapeutics aims to provide patients with chronic skin conditions, like plaque psoriasis, freedom from their condition by achieving high rates of complete disease clearance with infrequent dosing. Oruka is advancing a portfolio of potentially best-in-class antibodies engineered by Paragon Therapeutics that target the mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.
Source: Oruka Therapeutics
